Anti-CD44 monoclonal antibody IM7

Drug Profile

Anti-CD44 monoclonal antibody IM7

Alternative Names: Anti-CD44 monoclonal antibody IM7.8.1; IM7; IM7.8.1

Latest Information Update: 31 Oct 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rush-Presbyterian-St. Lukes Medical Center
  • Developer Hebrew University of Jerusalem; Imperial College of Science, Technology and Medicine; Rush-Presbyterian-St. Lukes Medical Center; Western General Hospital
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 09 Nov 2000 No-Development-Reported for Multiple sclerosis in United Kingdom (Unknown route)
  • 09 Nov 2000 No-Development-Reported for Multiple sclerosis in USA (Unknown route)
  • 09 Nov 2000 Preclinical development for Rheumatoid arthritis in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top